FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileArovella Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALA.AX
Arovella Therapeutics Limited Stock AnalysisComprehensive stock analysis for Arovella Therapeutics Limited (ALA.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisALA.AX
ALA.AX
Arovella Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALA.AX
  1. Home
  2. Stocks
  3. Arovella Therapeutics Limited

Arovella Therapeutics Limited

🇦🇺ALA.AX•ASX

Arovella Therapeutics Limited

🇦🇺ALA.AX•ASX

Your view on ALA.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Arovella Therapeutics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Nicole van der Weerden
Headquarters
Corporate One, Preston, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Nicole van der Weerden
Headquarters
Corporate One, Preston, VIC, AU
Description

Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally.

Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers.

Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment.

Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London.

Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Arovella Therapeutics Limited. Starting points for Arovella Therapeutics Limited: EPS -AUD 0.0057, beta 0.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Arovella Therapeutics Limited. Arovella Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Arovella Therapeutics Limited. Trailing twelve-month EPS for Arovella Therapeutics Limited stands at -AUD 0.0057. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Arovella Therapeutics Limited. Arovella Therapeutics Limited has reported as a listed company since 2002. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ALA.AX12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PBLSParabilis Medicines, Inc.HealthcareNASDAQ$3.3B
PBMPsyence Biomedical Ltd.HealthcareNASDAQ$56,486
PBMWWPsyence Biomedical Ltd. WarrantHealthcareNASDAQ$973
PBYIPuma Biotechnology, Inc.HealthcareNASDAQ$364.5M
PCSAProcessa Pharmaceuticals, Inc.HealthcareNASDAQ$4.4M
PCVXVaxcyte, Inc.HealthcareNASDAQ$8.8B
PDSBPDS Biotechnology CorporationHealthcareNASDAQ$43.4M
PEPGPepGen Inc.HealthcareNASDAQ$261.8M
PFNDPathfinder Cell Therapy, Inc.HealthcareOTC$66,716
PGENPrecigen, Inc.HealthcareNASDAQ$1.5B
PHARPharming Group N.V.HealthcareNASDAQ$814.5M
PHATPhathom Pharmaceuticals, Inc.HealthcareNASDAQ$378.8M
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Arovella Therapeutics Limited. Coverage tracks Arovella Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Arovella Therapeutics Limited.

ALA.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1